ArticlePulse (Basel, Switzerland)
Trends and Potential Risk Factors of Lower Extremity Peripheral Arterial Disease: Results from the Global Burden of Disease Study 2021.
Article in Pulse (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Triglyceride-Glucose Index Combined With Obesity Indices and Lower Extremity Artery Disease in Type 2 Diabetes: A Sex-Stratified Analysis.Endocrinology, diabetes & metabolism · 2026Article
- Global Burden, Attributable Risk Factors, and Future Projections of Lower Extremity Peripheral Arterial Disease Among Postmenopausal Women.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lower extremity peripheral arterial disease (LEPAD), causing reduced limb blood flow and significant morbidity, is a major global health concern. Understanding its burden and attributable risk factors is crucial for public health planning. The aim of this study was to quantify the global, regional, and national burden of LEPAD and disability-adjusted life years (DALYs) lost attributable to key risk factors from 1990 to 2021. Methods: This analysis utilized data from the Global Burden of Disease Study 2021. It employed multisource data and advanced statistical modeling to estimate LEPAD prevalence, incidence, mortality, DALYs, and risk factor attribution across 204 countries and territories. Results: In 2021, there were 113.7 million LEPAD survivors and 10.0 million new cases globally, with females comprising 67.0% of prevalent cases. LEPAD caused 67,000 deaths and 1.5 million DALYs. Six key risk factors accounted for most attributable DALYs: high fasting plasma glucose (36.06%), kidney dysfunction (28.64%), smoking (25.04%), hypertension (21.72%), lead exposure (15.05%), and high body mass index (BMI, 8.75%). Low- and middle-income countries bore a disproportionate burden (68.8% of incident cases, 60.9% of DALYs). While global incidence and mortality modestly declined since 1990, increases occurred in lower-middle and low socio-demographic index regions. Conclusion: LEPAD imposes a substantial global burden, disproportionately affecting females and populations in low-resource settings. Modifiable metabolic (glucose, kidney function, BMI, hypertension) and behavioral (smoking) risks dominate. Targeted interventions, especially in high-burden regions experiencing increasing trends, are urgently needed to mitigate LEPAD-related morbidity and mortality. Future research should focus on effective interventions and healthcare access barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.